Ronald Andrews Is The CEO, President & Director of OncoCyte Corporation (NASDAQ:OCX) And They Just Picked Up 11% More Shares
Even if it's not a huge purchase, we think it was good to see that Ronald Andrews, the CEO, President & Director of OncoCyte Corporation (NASDAQ:OCX) recently shelled out US$53k to buy stock, at US$4.79 per share. That purchase might not be huge but it did increase their holding by 11%.
View our latest analysis for OncoCyte
OncoCyte Insider Transactions Over The Last Year
Notably, that recent purchase by CEO, President & Director Ronald Andrews was not the only time they bought OncoCyte shares this year. Earlier in the year, they paid US$2.37 per share in a US$104k purchase. We do like to see buying, but this purchase was made at well below the current price of US$4.69. Because the shares were purchased at a lower price, this particular buy doesn't tell us much about how insiders feel about the current share price.
OncoCyte insiders may have bought shares in the last year, but they didn't sell any. They paid about US$2.04 on average. We don't deny that it is nice to see insiders buying stock in the company. However, we do note that they were buying at significantly lower prices than today's share price. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction!
OncoCyte is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.
Does OncoCyte Boast High Insider Ownership?
Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. A high insider ownership often makes company leadership more mindful of shareholder interests. OncoCyte insiders own about US$28m worth of shares. That equates to 6.6% of the company. While this is a strong but not outstanding level of insider ownership, it's enough to indicate some alignment between management and smaller shareholders.
So What Does This Data Suggest About OncoCyte Insiders?
The recent insider purchase is heartening. And the longer term insider transactions also give us confidence. But we don't feel the same about the fact the company is making losses. Given that insiders also own a fair bit of OncoCyte we think they are probably pretty confident of a bright future. While we like knowing what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. Our analysis shows 5 warning signs for OncoCyte (1 shouldn't be ignored!) and we strongly recommend you look at them before investing.
If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.
This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
